Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503150 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL29332226 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL29332222 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL18503187 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL10136277 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL18503217 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL18503160 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL18503196 | 1.00 | HTT (0.52) | HTTTHRBMEN1KMT2AMAPT | |
| SCHEMBL2182488 | 0.98 | HTT (0.48) | HTTTHRBMEN1KMT2AMAPT | |
| Pentane SCHEMBL27657066 | 0.95 | HTT (0.46) | HTTTHRBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239930-A1 | FUNCTIONALIZED MALEIC ACID COPOLYMERS FOR ENHANCED BIOACTIVITY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-07-18 | — | — | US | disclosed |
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-102271732-A | Nanochannel devices and related methods | — | 2011-12-07 | — | — | CN | disclosed |
| US-7993613-B2 | aldoxime extractants with optional ketoxime extractants; branched chain ether equilibrium modifiers; 2-hydroxy-5-heptylbenzaldoxime; tert-butyl octyl ether; copper sulfate | COGNIS IP MANAGEMENT GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| EP-2104542-A2 | MORE EFFICIENT ETHER MODIFIERS FOR COPPER EXTRACTANT FORMULATIONS | Cognis IP Management GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20080175772-A1 | MORE EFFICIENT ETHER MODIFIERS FOR COPPER EXTRACTANT FORMULATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008088473-A2 | MORE EFFICIENT ETHER MODIFIERS FOR COPPER EXTRACTANT FORMULATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | HTT 1255/4885THRB 92/4885MEN1 534/4885 |
| US-20240239930-A1 | FUNCTIONALIZED MALEIC ACID COPOLYMERS FOR ENHANCED BIOACTIVITY | MDH2, ME1, DDAH1 | HTT 4801/4885THRB 295/4885MEN1 234/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | HTT 1183/4885THRB 2080/4885MEN1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.